Professor Malecki joins MCT editorial board
Marek Malecki, M.D., Ph.D., is President of the Phoenix Biomolecular Engineering Foundation, San Francisco, CA, USA, and Principal Investigator on the Program Project, at the National Institutes of Health, Bethesda, MD, USA. He is a physician specialized in Oncology. He is a Visiting Professor at the University of Wisconsin, St James School of Medicine, and Medical Center for Postgraduate Training of Physicians, while teaching Oncology, Pharmacology, and Pharmacogenetics/Pharmacogenomics. He was elected by the faculty and students to the Rho Chi Honor Society for Excellence in Teaching and as the Faculty Role Model.
His primary effort, as a physician and a scientist, is dedicated to developing genomics based targeted therapies of cancer, which are specifically designed for individual patients. These efforts include modeling of interacting molecules, genomic and molecular engineering, and synthetic genomics. He is the first author on the articles indexed on PubMed and freely available through PMC describing these endeavors. His work resulted in developing a novel , genomics based, paradigm in therapy of cancer.
He is the Primary Inventor on the patents at USPTO and WIPO claiming novel genomics guided therapeutics for immunotherapy and gene therapy. His inventions propelled starting up pharmaceutical companies, which are manufacturing diagnostics and therapeutics for genomics based personalized therapy of cancer, which were recently invited for presenting at the 7th Precision Medicine World Congress and 24th International Molecular Medicine Conference. His novel therapeutics have successfully passed Phase I Clinical Trials and getting promising results in the currently pursued Phase II.
Professor Malecki is the Editor-in-Chief of Journal of Stem Cell Research and Therapy , Journal of Genetic Syndromes and Gene Therapy, British Journal of Biotechnology, Section Editor at the Clinical and Translational Medicine, and Editor in Frontiers in Genetics, Frontiers in Bioengineering and Biotechnology, Journal of Cancer research and Therapy. He is a member of American Medical Association and American Society for Medical Genetics.